TechFlow, August 5 — According to BusinessWire, U.S. pharmaceutical company MEI Pharma (Nasdaq: MEIP) announced the acquisition of 929,548 Litecoin (LTC) tokens at an average purchase price of $107.58, totaling approximately $110 million. The company has become the first publicly traded U.S. firm to adopt Litecoin as a primary reserve asset.
Earlier, MEI Pharma completed a $100 million private placement and added Litecoin to its treasury reserves.




